31 May 2016 15:20
PRESS RELEASE
Proteome Sciences plc
(the "Company" or the "Group")
Publication of Annual Report
31 May, 2016: The Company announces that its Annual Report and Accounts for the year ended 31 December 2015, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company's website at www.proteomics.com, and will be posted to shareholders imminently.
ENDS
For further information please contact:
Proteome Sciences plc | |
Christopher Pearce, Executive Chairman | |
Dr. Ian Pike, Chief Operating Officer | Tel: +44 (0)1932 865065 |
Geoff Ellis, Finance Director | |
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson |
Tel : +44 (0)20 7220 0563 |
Public Relations | |
IKON Associates | Email: adrian@ikonassociates.com |
Adrian Shaw | Tel: +44 (0)1483 271291 |
Mobile +44(0)7979 900733 | |
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant®, TMTcalibrator™) and in protein biomarker discovery, validation and assay development.
PS Biomarker Services® provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.
Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.
Proteome (PRM)